Rego and TAS-102 for CRC
Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

Released: April 06, 2022

Expiration: April 05, 2023

Nilofer S. Azad
Nilofer S. Azad, MD
Kanwal Raghav
Kanwal Raghav, MD

Activity

Progress
1
Course Completed

In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:

  • Current use of regorafenib and TAS-102 monotherapy
  • Combination therapy with regorafenib and PD-1 inhibitors
  • Adding bevacizumab to TAS-102